The abstract is read at the publisher; the summary is JClub's.
Low-dose IL-2 did not expand regulatory T cells in alemtuzumab-treated relapsing-remitting multiple sclerosis patients more than 6 months after therapy, despite prior in vitro and mouse selectivity.
- Why it matters: Alemtuzumab can trigger delayed autoimmunity in RRMS, and IL-2–driven Treg expansion is a promising tolerance strategy that is linked to improved markers in other diseases.
- What they did: The team tested low-dose IL-2 using in vitro assays, a CD52-expressing transgenic mouse model, and a prospective open-label mechanistic study in RRMS patients given IL-2 at 0.3 × 106 IU/m2 twice a week.
- The result: Although IL-2 increased high-affinity IL-2 receptor expression on naïve CD4+ Teffs in patients and preferentially expanded Tregs only at later mouse time points (>6 months), the clinical study found IL-2 was well tolerated yet unexpectedly failed to expand Tregs.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.